DDInter1724 DDInter1676
Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps in the biosynthesis of nucleic acids and proteins which are necessary for bacterial growth and division, and using them in conjunction helps to slow the development of bacterial resistance. In this combination, sulfamethoxazole is useful for the treatment of a variety of bacterial infections, including those of the urinary, respiratory, and gastrointestinal tracts.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Sulfamethoxazole {u} (Compound) resembles {v} (Compound) Sulfisoxazole
Sulfamethoxazole {u} (Compound) binds {v} (Gene) CYP2C8
Sulfamethoxazole {u} (Compound) upregulates {v} (Gene) SLC1A4
Sulfamethoxazole {u} (Compound) is included by {v} (Pharmacologic Class) Sulfonamides
Sulfamethoxazole {u} (Compound) downregulates {v} (Gene) RPS4Y1
Sulfamethoxazole {u} (Compound) causes {v} (Side Effect) Purpura
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Toremifene
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enzalutamide
Sulfamethoxazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methoxsalen
Sulfamethoxazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tetracaine
Sulfamethoxazole (Compound) resembles Sulfisoxazole (Compound)
Sulfamethoxazole (Compound) binds CYP2C8 (Gene)
Sulfamethoxazole (Compound) upregulates SLC1A4 (Gene)
Sulfamethoxazole (Compound) is included by Sulfonamides (Pharmacologic Class)
Sulfamethoxazole (Compound) downregulates RPS4Y1 (Gene)
Sulfamethoxazole (Compound) causes Purpura (Side Effect)
Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Toremifene
Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Sulfamethoxazole may cause a moderate interaction that could exacerbate diseases when taken with Methoxsalen
Sulfamethoxazole may cause a moderate interaction that could exacerbate diseases when taken with Tetracaine